RenovoRx Inc (RNXT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $50.18M
Last updated: Nov 17, 2026 at 4:29 PM ET
RenovoRx Inc (RNXT) Statistics
RenovoRx (RNXT) has a market cap of $50.18M and an enterprise value of $39.78M. It kept -469.02% of revenue as net income over the last 12 months. Revenue grew 199.14% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 20.73% below the market cap, as cash exceeds debt.
| Market Cap | $50.18M |
|---|---|
| Enterprise Value | $39.78M |
| Latest price (Nov 17, 2026) | $1.04 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 18.1x and 5.4x.
| P/S Ratio | 18.1x |
|---|---|
| Forward P/S | 13.0x |
| P/B Ratio | 5.4x |
Price Statistics
The stock is up 38.67% over 52 weeks and trades 25.71% below its 50-day average.
| Beta (1Y) | 1.59 |
|---|---|
| 52-Week Change | +38.67% |
| 1-Month Change | -10.34% |
| 3-Month Change | -20.91% |
| 6-Month Change | +29.05% |
| 5-Year Change | -74.32% |
| Total Return (1Y) | +38.67% |
| Total Return (5Y CAGR) | -30.55% |
| Max Drawdown (1Y) | -62.11% |
| Max Drawdown (3Y) | -68.01% |
| Sharpe Ratio (1Y) | 0.35 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $1.40 |
| 200-Day Average | $1.11 |
| 52-Week Range | $0.73 to $2.59 |
| RSI (14 Days) | 38.0 |
| Average Volume (20 Days) | 463.72K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.65x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.65x |
|---|---|
| Quick Ratio | 5.49x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -140.24% and return on assets is -104.69% over the last 12 months.
| Return on Equity (ROE) | -140.24% |
|---|---|
| Return on Assets (ROA) | -104.69% |
| Asset Turnover | 0.23x |
| Inventory Turnover | 1.22x |
| Receivables Turnover | 5.10x |
| Cash Conversion Cycle | -373 days |
Scores
RNXT has an Altman Z-Score of -0.88, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.88 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $2.78M over the last 12 months.
| Revenue | $2.78M |
|---|---|
| Revenue Growth (YoY) | +199.14% |
| Gross Profit | $2.33M |
| Operating Income | -$13.58M |
| Pretax Income | -$13.02M |
| Net Income | -$13.02M |
| Reported EPS (TTM) | -$0.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 74.60% of the $12.44M in total assets.
| Cash and Equivalents | $10.40M |
|---|---|
| Total Debt | $0 |
| Net Cash | $10.40M |
| Net Cash Per Share | $0.22 |
| Working Capital | $9.72M |
| Shareholder Equity | $9.28M |
| Book Value Per Share | $0.19 |
| Total Assets | $12.44M |
| Total Liabilities | $3.15M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $90.00K of capital spending, operating cash flow left -$12.22M of free cash flow.
| Operating Cash Flow | -$12.13M |
|---|---|
| Capital Expenditures | $90.00K |
| Free Cash Flow | -$12.22M |
| FCF Per Share | -$0.27 |
| Depreciation and Amortization | $12.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -489.05%.
| Gross Margin | 84.04% |
|---|---|
| Operating Margin | -489.05% |
| Pretax Margin | -469.02% |
| Net Margin | -469.02% |
| FCF Margin | -440.38% |
Dividends and Yields
RNXT does not pay a dividend.
| Buyback Yield | -17.94% |
|---|---|
| Shareholder Yield | -17.94% |
Peer Position
Against 7 similar companies, RNXT has the 5th highest P/S.
P/S RatioPeer median 24.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.21%
| P/S Ratio | 18.1x vs 24.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +199.14% vs +7.21% median |
Analyst Forecast
Consensus estimates put revenue growth at 205.70% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +205.70% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RNXT
What is RNXT's market cap?
RenovoRx has a market cap of $50.18M. Its enterprise value, which adds debt and subtracts cash, is $39.78M.
How many shares of RNXT are outstanding?
RenovoRx has 48.19M shares outstanding. The count is up 31.51% from a year earlier.
Does RNXT pay a dividend?
No. RenovoRx does not pay a dividend.
How much debt does RNXT have?
RenovoRx has $0 of total debt and $10.40M of cash and equivalents, a net cash position of $10.40M.
RNXT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors